Vimian Group AB (publ) (VIMIAN.ST)
SEK 42.2
(2.93%)
SEK 42.2
(2.93%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | 9.84 Million EUR | 236.7% |
| 2022 | -7.19 Million EUR | -209.29% |
| 2021 | 6.58 Million EUR | -87.53% |
| 2020 | 52.79 Million EUR | 4402.69% |
| 2019 | -1.22 Million EUR | -55.32% |
| 2018 | -790 Thousand EUR | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | 3.5 Million EUR | 158.45% |
| 2024 Q2 | 4.87 Million EUR | 39.09% |
| 2024 Q3 | -2.12 Million EUR | -143.65% |
| 2023 Q4 | -5.99 Million EUR | -180.61% |
| 2023 Q2 | 2.99 Million EUR | -44.62% |
| 2023 Q3 | 7.43 Million EUR | 148.23% |
| 2023 Q1 | 5.4 Million EUR | 125.69% |
| 2023 FY | 9.84 Million EUR | 236.7% |
| 2022 Q4 | -21.04 Million EUR | -1215.13% |
| 2022 FY | -7.19 Million EUR | -209.29% |
| 2022 Q3 | -1.6 Million EUR | -116.01% |
| 2022 Q2 | 9.99 Million EUR | 84.22% |
| 2022 Q1 | 5.42 Million EUR | 167.98% |
| 2021 Q2 | -3.07 Million EUR | -138.87% |
| 2021 FY | 6.58 Million EUR | -87.53% |
| 2021 Q4 | 2.02 Million EUR | 836.0% |
| 2021 Q3 | -275 Thousand EUR | 91.06% |
| 2021 Q1 | 7.91 Million EUR | -85.24% |
| 2020 Q1 | 579 Thousand EUR | 0.0% |
| 2020 Q3 | 233 Thousand EUR | 124.0% |
| 2020 Q2 | -971 Thousand EUR | -267.7% |
| 2020 Q4 | 53.6 Million EUR | 22906.01% |
| 2020 FY | 52.79 Million EUR | 4402.69% |
| 2019 FY | -1.22 Million EUR | -55.32% |
| 2018 FY | -790 Thousand EUR | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| AroCell AB (publ) | -59.29 Million SEK | 116.594% |
| Devyser Diagnostics AB (publ) | -53.6 Million SEK | 118.358% |
| Immunovia AB (publ) | -309.43 Million SEK | 103.18% |
| Prostatype Genomics AB (publ) | -41.43 Million SEK | 123.748% |
| SenzaGen AB | -22.09 Million SEK | 144.531% |
| Spermosens AB | -12.2 Million SEK | 180.643% |